A Randomized, Open Label Trial of the Safety and Efficacy of DEB025/Alisporivir in Combination With Pegylated Interferon-α2a and Ribavirin (Peg-INFα2a/RBV) and Boceprevir in Combination With Peg-INFα2a/RBV in African American Treatment-naïve Patients With Chronic Hepatitis C Genotype 1
Phase of Trial: Phase III
Latest Information Update: 20 Jan 2017
At a glance
- Drugs Alisporivir; Boceprevir; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Novartis
- 04 Apr 2016 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 20 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 08 Feb 2012 Additional location [USA] identified as reported by ClinicalTrials.gov.